Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
More state Medicaid programs consider covering GLP-1 drugs
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity. Currently, just 13 state Medicaid programs cover GLP-1s for obesity. Most of the states that don’t cite the drugs’ high cost.
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds
The survey of the 50 states and the District of Columbia found that just 12 Medicaid programs covered the drugs to treat obesity as of July 2024 with some limits on use. Half of the states without coverage said they are considering adding them or evaluating their coverage,
Study finds high costs, few benefits associated with GLP-1 weight loss drugs
A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond dropping pounds.
1d
on MSN
Do 'Natural GLP-1 Supplements' Actually Work? Here's What Experts Think.
Food naturally boosts your body’s GLP-1 levels, explained Dr. Sun Kim, an endocrinologist at Stanford Health Care in ...
Medpage Today on MSN
9h
GLP-1 Drugs Tied to Reduced Risk of Uterine Fibroids
Among patients who took at least two doses of medication, GLP-1 receptor agonists were associated with a significantly lower ...
BioSpace
17h
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
Healthline
3d
How Ozempic, GLP-1 Weight Loss Drugs Affect the Brain to Curb Substance Misuse
A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...
Medscape
16h
Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1D
An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.
Medpage Today on MSN
2d
No X-Ray Proof of Rare Surgical Complication Tied to GLP-1 Agonists
However, the number of verified aspiration events came out to just 20 events, all identified from anesthesia notes and all in ...
HR Dive
13h
Employees are asking about GLP-1 coverage. What should employers do?
For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...
Futurism on MSN
1d
The Diet Industry Is Reportedly in Total Meltdown Over GLP-1 Weight Loss Drugs
With weight loss injectables like Ozempic and Mounjaro taking the world by storm, the diet industry is seemingly being left ...
11d
on MSN
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
7d
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
Transenteric delivery via the RaniPill yielded 80% relative bioavailability versus SC and differences between PK parameters ...
19h
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...
7d
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Weight loss
Noom
Food and Drug Administration
Novo Nordisk
Feedback